Observational Recruiting
NCT06907771 on ClinicalTrials.gov
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
- Sponsor: Hôpital d'Hautepierre
- Enrollment: 130 (Estimated)
- Study start: 2024-04-22 (Actual)
- Primary completion: 2025-12-22 (Estimated)
- Study completion: 2025-12-22 (Estimated)
- Allocation: N/a
- InterventionModel: N/a
- Masking: None
- PrimaryPurpose: Other
Brief Summary
Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage.
Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.
Conditions
- Ovarian Cancer
Primary Outcome Measures
- Study of progression-free survival at 36 months (At 36 months)
Countries
France
Locations and Investigators
-
Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France, Strasbourg, France (Recruiting)
- Lise LECOINTRE, MD
- Lise LECOINTRE, MD (Principal Investigator)
- Marie LORHO, MD